Loading...
Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects
Alemtuzumab was first used in multiple sclerosis in 1991. It is a monoclonal antibody which is directed against CD52, a protein of unknown function on lymphocytes. Alemtuzumab causes a lymphopenia, following which homeostatic reconstitution leads to prolonged alteration of the immune repertoire. Thi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3629751/ https://ncbi.nlm.nih.gov/pubmed/23634277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622313479137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|